Lexaria Bioscience Corp. announced on April 3, 2025, that enrollment of patients for all five study arms in its Phase 1b, 12-week chronic study GLP-1-H24-4 in Australia has been completed on schedule.
The study overenrolled, entering a total of 24 patients per study arm versus the original target of 20. This completion signifies the important 'last patient in' clinical study milestone, meaning that treatment of all patients is expected to be completed approximately twelve weeks from this date.
This achievement brings Lexaria closer to the series of patient sample analyses, data compilation, and reporting, which is currently projected to occur during the fourth quarter of 2025. The study evaluates DehydraTECH-semaglutide, DehydraTECH-tirzepatide, and DehydraTECH-cannabidiol, promoting oral delivery over injections.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.